Brief: Deciphera Receives European Commission Approval Of Romvimza (Vimseltinib)
17/09/2025 21:10
Sept 17 (Reuters) - Ono Pharmaceutical Co Ltd 4528.T: DECIPHERA RECEIVES EUROPEAN COMMISSION APPROVAL OF ROMVIMZA™ (VIMSELTINIB) FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) Source text: ID:nBw1fYMwDa Further company coverage: 4528.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours